E2F1 as a molecular drug target in ovarian cancer

Expert Opin Ther Targets. 2019 Mar;23(3):161-164. doi: 10.1080/14728222.2019.1579797. Epub 2019 Feb 8.

Authors

Rossella Farra¹, Barbara Dapas¹, Mario Grassi², Fabio Benedetti³, Gabriele Grassi¹

Affiliations

¹ a Department of Life Sciences , Cattinara University Hospital, Trieste University , Trieste , Italy.
² b Department of Engineering and Architecture , University of Trieste , Trieste , Italy.
³ c Dipartimento di Scienze Chimiche e Farmaceutiche , Università degli Studi di Trieste , Trieste , Italy.

PMID: 30724632
DOI: 10.1080/14728222.2019.1579797

No abstract available

Keywords: E2F1; Ovarian cancer; PIN-1; cyclinD1.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / pharmacology*
E2F1 Transcription Factor / metabolism*
Female
Humans
Molecular Targeted Therapy
Ovarian Neoplasms / drug therapy*
Ovarian Neoplasms / pathology

Substances

Antineoplastic Agents
E2F1 Transcription Factor
E2F1 protein, human